By Melissa Patrick
Kentucky Health News
Kentucky Attorney General Russell Coleman laid out his mission for the next phase of the Kentucky Opioid Abatement Advisory Commission Tuesday, calling on them to focus on building a "gold-standard statewide prevention program" with settlements paid by opioid makers and distributors.
![]() |
| Attorney General Russell Coleman (Photo provided) |
Coleman called on the commission to focus on prevention as it considers the coming round of grant applications. "I encourage you to place a strong emphasis on boosting Kentucky’s critically needed prevention efforts," he said.
Coleman added that his office is in the midst of developing new youth prevention initiatives that focus on education.
"When we're in an environment where children are experimenting with these dangerous substances as early as 11 – we're seeing it in late elementary school – we have to have conversations with our kids earlier and earlier," he said. Later adding, "It's our responsibility, yours and mine, to prepare them for this threat they are facing in a new threat environment."
When asked what his vision for a statewide prevention program would look like, Coleman told reporters that it will be important to look at what states such as Georgia, Tennessee, Virginia and Mississippi are doing.
He said Virginia has a robust "one pill can kill" prevention effort and Mississippi had rolled out a "very creative approach that uses name, image and likeness of Ole Miss players to be able to engage and get that message out there, to permeate in the social media space. I would love to institute a program here that looks a lot like what is ongoing in the state of Mississippi."
As for treatment and enforcement, Coleman said Kentucky is doing a great job in most of the state when it comes to treatment beds, and he told reporters that the drug cartels in Mexico are doing a great job of getting these substances into the U.S., which means collaboration is key, saying there is a need to "tear down the silos between federal, state and local" enforcement efforts.
"Again, we have to do very strong enforcement piece, but it has to be alongside a stronger prevention effort and continuing to treat our addicted neighbors," he said."In that spirit, I respectfully ask this commission to step back from previous proposals to allocate $42 million to ibogaine research and the unproven, expensive clinical trial for a psychedelic that is, as you know, currently a Schedule 1 drug in the United States."
"If someone brings forward an ibogaine research proposal that fits the criteria of this new innovative grant proposal, I hope this commission will give it full and fair consideration," he said. "It's not zero sum."









